# SKYSCRAPER-01 (NCT04294810)

> A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04294810
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab; Tiragolumab; Matching Placebo
- Enrollment: 620
- Primary outcome: Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set
- Primary outcome: Overall Survival (OS) in the Primary Analysis Set
- Primary outcome: Percentage of Participants With Adverse Events (AEs)
- Primary outcome: Percentage of Participants With Cytokine-Release Syndrome (CRS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 30
- Podcasts: 2
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=skyscraper-01-nct04294810

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04294810", "email": "<work email>"}; the inbox owner confirms by the emailed link.